CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 155 filers reported holding CHINOOK THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $55,908,861 | +66.0% | 1,455,202 | 0.0% | 0.32% | +77.0% |
| Q1 2023 | $33,687,926 | -49.3% | 1,455,202 | -42.6% | 0.18% | -54.1% |
| Q4 2022 | $66,393,472 | +33.3% | 2,534,102 | 0.0% | 0.40% | +22.4% |
| Q3 2022 | $49,820,000 | +12.4% | 2,534,102 | 0.0% | 0.33% | +29.9% |
| Q2 2022 | $44,321,000 | +16.1% | 2,534,102 | +8.6% | 0.25% | +14.6% |
| Q1 2022 | $38,186,000 | +0.3% | 2,334,102 | 0.0% | 0.22% | +18.4% |
| Q4 2021 | $38,069,000 | +56.8% | 2,334,102 | +22.6% | 0.18% | +72.9% |
| Q3 2021 | $24,283,000 | +59.2% | 1,903,069 | +76.1% | 0.11% | +59.7% |
| Q2 2021 | $15,255,000 | +31.1% | 1,080,393 | +44.3% | 0.07% | +34.0% |
| Q1 2021 | $11,635,000 | -2.0% | 748,693 | 0.0% | 0.05% | +11.1% |
| Q4 2020 | $11,874,000 | – | 748,693 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |